Ticker
EBSCompany Name
EMERGENT BIOSOLUTIONS INCSector
HealthcareIndustry
Drug Manufacturers - Specialty & GenericExchange
NYSEDate | Capital Expenditure | Free Cash Flow | Net Cash Flow - Operations |
---|---|---|---|
6/30/2025 | $ -32.1M | $ 201.1M | $ 169M |
3/31/2025 | $ -30.3M | $ 140.4M | $ 110.1M |
12/31/2024 | $ 15M | $ 43.7M | $ 58.7M |
9/30/2024 | $ 25M | $ 145.7M | $ 170.7M |
6/30/2024 | $ 39.4M | $ 37.6M | $ 77M |
3/31/2024 | $ 47.3M | $ -132.2M | $ -84.9M |
12/31/2023 | $ 51.6M | $ -257.9M | $ -206.3M |
9/30/2023 | $ 63.8M | $ -209.4M | $ -145.6M |
6/30/2023 | $ 79.1M | $ -358.7M | $ -279.6M |
3/31/2023 | $ 98.7M | $ -279.5M | $ -180.8M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CF - Operations - CapEx
(=) FCF
FCF for EMERGENT BIOSOLUTIONS INC is calculated as follows: CF - Operations [ $ 413M ] - CapEx [ $ 141.1M ]
(=) FCF [ $ 271.9M ]
Minimum
Jun 30, 2023
Maximum
Dec 31, 2020
Average
Median
filtered constituents | 3.3K |
---|---|
min | $ -356.66M |
max | $ 390M |
average | $ 28.76M |
median | $ 461K |
std | $ 117.98M |